This site uses cookies, by using this site you accept our cookie policy.

Whittington Health NHSUCL


These are important guidelines relating to type 2 diabetes and recent alerts which may have a bearing on current management.

For the most up to date guidance on a specific topic, see NICE Evidence search

NICE guidelines

The National Institute for Health and Care Excellence, also known as NICE, was set up in the UK in 1999.

Its main aim was to reduce the variation in the availability and quality of services in the NHS and to resolve uncertainties about how best to manage certain conditions.

Here you will find a list of the main areas covered by NICE guidance in relation to type 2 diabetes

‘TA’ refers to technology appraisals
‘CG’ refers to clinical guidance
‘PH’ refers to public health guidance

General guidance


2014: Canagliflozin in combination therapy for treating type 2 diabetes (TA315)

2008: Diabetes – insulin pump therapy (TA151)

2006: Diabetes (type 1 and 2) – inhaled insulin (TA113)

2015: Type 1 diabetes in adults: diagnosis and management (NG17)

Foot care

2015: Diabetic foot problems: prevention and management (NG19)

Eye care

2013: Ranibizumab for treating diabetic macular oedema (TA274)

Education and self-management

2015: Type 1 diabetes in adults: diagnosis and management (NG17)

Prevention of diabetes

2012: Preventing type 2 diabetes: risk identification and interventions for individuals at high risk (PH38)

2011: Preventing type 2 diabetes – population and community interventions (PH35)

Diabetes in pregnancy

2015: Diabetes in pregnancy: management from preconception to the postnatal period (NG3)

2008: Antenatal care (CG62)

SIGN guidance from the Scottish intercollegiate Guidelines Network

SIGN was founded in 1993 to improve the quality of care in Scotland by developing and disseminating evidence based guidance for the NHS in Scotland.

There is currently one main document published by SIGN in relation to diabetes.

2010: Management of diabetes (116)

MHRA updates

The MHRA is the Medicines and Healthcare products Regulatory Agency. It is a government agency which aims to promote and maintain the safety of medicines and medical devices.

When a safety concern is raised about a medication used in diabetes, the MHRA publish very useful summaries of the evidence and what action should be taken.

2011: New advice on risk of bladder cancer with the anti-diabetic pioglitazone

2010: Rosiglitazone

SGLT-2 inhibitors and risk of diabetic keto-acidosis


Information aimed at patients

Information aimed at health professionals

The British National Formulary (BNF)